Stable IOP in BRVO/ CRVO treated with Ozurdex®, a real-life observational study in a single centre in Switzerland

Session Details

Session Title: Free Paper Session 23: Vascular Diseases & Diabetic Retinopathy VI

Session Date/Time: Sunday 10/09/2017 | 08:00-09:30

Paper Time: 08:36

Venue: Room 120

First Author: : Y.Louati SWITZERLAND

Co Author(s): :    C. Bergin   S. Ezziat   P. de Gottrau   V. Vaclavik                    

Abstract Details

Purpose:

To report, mean IOP, number of antiglaucoma medication, duration of antiglaucoma treatment, time before anti-VEGF switch and reasons for switch as well as mean CMT at 1 week, 1 month, 4 months after Ozurdex® in BRVO/ CRVO.

Setting:

Retrospective study of 28 eyes treated with dexamethasone implant for macular edema secondary to CRVO/BRVO

Methods:

Obervational study. All eyes treated with Ozurdex® in the Ophthalmology Department, Fribourg Canton Hospital, Switzerland, were identified over a period of 6 months. BRVO and CRVO cases were selected. IOP, CMT (Optical coherence tomography (OCT)), number of antiglaucoma medication at baseline, 1 week,1 month 4 months after Ozurdex®, as well as time before anti-VEGF switch and reasons for switch were identified both retrospectively and prospectively. Number of total Ozurdex® per eye was searched for.

Results:

84 Ozurdex® injections performed. 66 Cases with BRVO/ CRVO were identified and selected, 18 were excluded (14 diabetic, 3 uveitic, 1 post-surgery macular edema). IOP went up at 1 week and 1 month but returned to baseline values at 4 months in both BRVO and CRVO. 3 eyes reached an IOP > 30 mmHg. No case of filtering surgery has been observed. Eyes treated with > 1 Ozurdex® quickly droped from 66 to 16 (2 IVT) , 11 (3IVT), 6 (4 IVT), 4 (5 IVT) and 1 (IVT). 12 were treated with antiglaucoma drops. 3 were under monotherapy, 6 under bitherapy, 2 under tritherapy and 1 under quadritherapy. Duration varied from 1 month to 21 months. No lifetime treatment was needed. 20 were switch to anti-VEGF. Reasons for switch were: HTIO, cataract acceleration, rubeosis, insurance problems, endophtalmitis suspicion, refusal to do more injections. 3 eyes already diagnosed with cataracts before Ozurdex® treatment needed phaco during the study.

Conclusions:

Modest elevation of mean IOP was observed at 1 week and 1 month in 37% of eyes. Stable IOP at 4 months was demonstrated, treated if required. Exaggerated fear for IOP elevation after Ozurdex® leaded to quick discontinuation of Ozurdex® therapy and switch to anti-VEGF.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy